Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
ClearPoint Neuro, Inc. completed its acquisition of IRRAS Holdings, Inc. on November 20, 2025 under an Agreement and Plan of Merger and Reorganization. The transaction was implemented through a two-step merger structure using Ignite Merger Sub, Inc. and ClearPoint’s second merger subsidiary.
In the pro forma filing, ClearPoint is treated as the acquirer for accounting purposes and the deal is accounted for as a business combination under GAAP (ASC 805). The pro forma condensed combined financial information was prepared to show estimated effects as if the merger occurred on September 30, 2025 for the balance sheet and January 1, 2024 for statements of operations.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026